{"id":"autologous-serum","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or discomfort"},{"rate":null,"effect":"Infection risk (from preparation/handling)"},{"rate":null,"effect":"Allergic reaction"}]},"_chembl":{"chemblId":"CHEMBL2109149","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Autologous serum eye drops are prepared from the patient's own blood serum and contain naturally occurring growth factors, immunoglobulins, and other bioactive molecules that mimic tears. When applied topically, these components promote epithelial cell proliferation, reduce inflammation, and support ocular surface healing. This approach is particularly useful in severe dry eye disease and other ocular surface disorders where conventional treatments are insufficient.","oneSentence":"Autologous serum is a patient's own blood serum used topically to provide growth factors and immunomodulatory components that promote tissue healing and reduce inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:27:54.611Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe dry eye syndrome/keratoconjunctivitis sicca"},{"name":"Ocular surface disease refractory to conventional therapy"},{"name":"Stevens-Johnson syndrome ocular complications"},{"name":"Graft-versus-host disease (ocular manifestations)"}]},"trialDetails":[{"nctId":"NCT03686124","phase":"PHASE1, PHASE2","title":"ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2019-05-14","conditions":"Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult","enrollment":375},{"nctId":"NCT06959771","phase":"PHASE1, PHASE2","title":"Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-16","conditions":"CD40L-HyperIgM Syndrome","enrollment":1},{"nctId":"NCT03267433","phase":"PHASE3","title":"Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2017-11-27","conditions":"Mantle Cell Lymphoma","enrollment":689},{"nctId":"NCT07486583","phase":"PHASE3","title":"Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients.","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-04-30","conditions":"Chronic Idiopathic Urticaria","enrollment":40},{"nctId":"NCT07473232","phase":"NA","title":"Comparison of Platelet-rich Plasma and Activated Cytokine-rich Serum Injection Treatments in Patients With Knee Osteoarthritis. (KOA PRP ACS)","status":"NOT_YET_RECRUITING","sponsor":"Pamukkale University","startDate":"2026-04-01","conditions":"Knee Arthritis Osteoarthritis, Platelet Rich Plasma Injection, Conditioned Serum","enrollment":60},{"nctId":"NCT01011920","phase":"PHASE2","title":"Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2009-11","conditions":"Central Nervous System Lymphoma","enrollment":227},{"nctId":"NCT06839326","phase":"NA","title":"Efficacy of Autologous Conditioned Serum in Temporomandibular Joint Disorder","status":"COMPLETED","sponsor":"Batman University","startDate":"2024-11-01","conditions":"Temporomandibular Joint Osteoarthritis","enrollment":75},{"nctId":"NCT07469865","phase":"NA","title":"Efficacy and Safety of 20% and 100% Autologous Serum Eye Drops in Patients With Severe Dry Eye Disease (AST)","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2021-11-30","conditions":"Dry Eye Disease","enrollment":46},{"nctId":"NCT05357482","phase":"PHASE1, PHASE2","title":"Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-05-12","conditions":"Sickle Cell Anemia, Beta Thalassemia","enrollment":40},{"nctId":"NCT00492050","phase":"PHASE2","title":"Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-08-02","conditions":"Waldenstrom's Macroglobulinemia","enrollment":46},{"nctId":"NCT02213913","phase":"PHASE1, PHASE2","title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2014-07-29","conditions":"Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell Lymphoma","enrollment":55},{"nctId":"NCT06475495","phase":"PHASE1, PHASE2","title":"Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2024-12-04","conditions":"Rheumatoid Arthritis","enrollment":13},{"nctId":"NCT05605899","phase":"PHASE3","title":"Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2023-02-10","conditions":"High-risk Large B-cell Lymphoma (LBCL)","enrollment":300},{"nctId":"NCT06364423","phase":"PHASE1, PHASE2","title":"Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-03","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic, B-Cell Chronic Lymphocytic Leukemia","enrollment":132},{"nctId":"NCT00716066","phase":"PHASE2","title":"Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2008-06","conditions":"Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune","enrollment":53},{"nctId":"NCT05601752","phase":"PHASE2","title":"ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)","status":"ACTIVE_NOT_RECRUITING","sponsor":"USWM CT, LLC","startDate":"2023-06-26","conditions":"Ovarian Cancer","enrollment":66},{"nctId":"NCT03942328","phase":"PHASE1, PHASE2","title":"Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-09-19","conditions":"Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":85},{"nctId":"NCT04224558","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":"Crohn Disease","enrollment":15},{"nctId":"NCT07348094","phase":"NA","title":"Guided Lateral Sinus Lifting Using Autologous Serum Albumin/Platelet-Rich Fibrin","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2026-01-26","conditions":"Sinus Perforation, Dental Implant Failure Nos","enrollment":45},{"nctId":"NCT07413172","phase":"PHASE2","title":"Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry Eye","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-03","conditions":"Dry Eye, Eye Diseases, Eyes Dry Chronic","enrollment":20},{"nctId":"NCT07410520","phase":"PHASE2","title":"PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-02-07","conditions":"Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)","enrollment":50},{"nctId":"NCT07407101","phase":"NA","title":"Impact of Filtration on Autologous Serum Eye Drops","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Limoges","startDate":"2026-04-30","conditions":"Dry Eye Syndrome (DES)","enrollment":10},{"nctId":"NCT06230224","phase":"PHASE3","title":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-02-15","conditions":"B-Cell Non-Hodgkin Lymphoma (B-NHL)","enrollment":216},{"nctId":"NCT05857371","phase":"PHASE2","title":"Safety and Potential Effect of Innovative Treatment by Adjuvant Injection of Stromal Vascular Fraction From Autologous Adipose Tissue of URethral Stenosis With Endoscopic Urethrotomy","status":"RECRUITING","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2024-03-13","conditions":"Urethral Stenosis","enrollment":20},{"nctId":"NCT05180097","phase":"PHASE2","title":"Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2022-11-01","conditions":"Hodgkin Lymphoma","enrollment":84},{"nctId":"NCT00882895","phase":"PHASE2","title":"Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2009-05-05","conditions":"Lymphoma, Non-Hodgkin","enrollment":18},{"nctId":"NCT04196413","phase":"PHASE1","title":"GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2020-06-04","conditions":"Glioma of Spinal Cord, Glioma of Brainstem","enrollment":97},{"nctId":"NCT07365306","phase":"PHASE2","title":"Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-12-30","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Mediastinal Large B-Cell Lymphoma","enrollment":43},{"nctId":"NCT06726538","phase":"PHASE1, PHASE2","title":"Investigating the Efficacy of Autologous, Adipose-derived Mesenchymal Stem Cell Therapy for the Treatment of Sexual Function Impairment in Women Aged 40-50","status":"COMPLETED","sponsor":"Vinmec Research Institute of Stem Cell and Gene Technology","startDate":"2023-10-01","conditions":"Female Sexual Dysfunction","enrollment":50},{"nctId":"NCT04047628","phase":"PHASE3","title":"Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-19","conditions":"Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis","enrollment":156},{"nctId":"NCT07020715","phase":"PHASE2","title":"A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2026-03-01","conditions":"Multiple Sclerosis","enrollment":14},{"nctId":"NCT07263347","phase":"","title":"DIEP Flap Breast Reconstruction: Perioperative Biomarkers and Outcomes","status":"NOT_YET_RECRUITING","sponsor":"Hubei Cancer Hospital","startDate":"2025-12","conditions":"Breast Neoplasms, Ischemia-Reperfusion Injury, Postoperative Complications","enrollment":30},{"nctId":"NCT07295691","phase":"NA","title":"Autologous Serum Eye Drops in Dry Eye Syndrome","status":"RECRUITING","sponsor":"The General Authority for Teaching Hospitals and Institutes","startDate":"2025-09-01","conditions":"Autologous Serum Eye Drops, Dry Eye Syndrome","enrollment":70},{"nctId":"NCT05672173","phase":"PHASE2","title":"Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-06-02","conditions":"Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome","enrollment":20},{"nctId":"NCT00692939","phase":"PHASE1, PHASE2","title":"Autologous Stem Cell Transplantation for Crohn's Disease","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2012-06-26","conditions":"Crohn's Disease","enrollment":20},{"nctId":"NCT05400590","phase":"","title":"Comparison of the Healing Properties on Corneal Cells of Groth Factor-enriched Plasma and Autologous Serum From Aniridia Patients","status":"RECRUITING","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2023-05-15","conditions":"Aniridia","enrollment":24},{"nctId":"NCT03352765","phase":"PHASE1","title":"A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-11-20","conditions":"Lymphoma","enrollment":28},{"nctId":"NCT04871607","phase":"PHASE2","title":"Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-11-02","conditions":"Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":33},{"nctId":"NCT02390869","phase":"PHASE3","title":"Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2014-05","conditions":"Lymphoma, Follicular","enrollment":128},{"nctId":"NCT04057833","phase":"PHASE1","title":"E-CEL UVEC Cells as an Adjunct Cell Therapy for the Arthroscopic Rotator Cuff Repair in Adults","status":"ENROLLING_BY_INVITATION","sponsor":"Hospital for Special Surgery, New York","startDate":"2019-11-20","conditions":"Rotator Cuff Tears, Muscle Atrophy or Weakness, Tendon Rupture - Shoulder","enrollment":20},{"nctId":"NCT05631899","phase":"PHASE1","title":"CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2023-04-03","conditions":"Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V","enrollment":9},{"nctId":"NCT03449108","phase":"PHASE2","title":"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-04-27","conditions":"Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone","enrollment":30},{"nctId":"NCT03233152","phase":"PHASE1, PHASE2","title":"A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2016-11-17","conditions":"Glioblastoma","enrollment":110},{"nctId":"NCT03113500","phase":"PHASE2","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2017-05-25","conditions":"Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive","enrollment":48},{"nctId":"NCT06550141","phase":"PHASE2","title":"Emapalumab Prevention of CAR-T Cell Associated Toxicities","status":"RECRUITING","sponsor":"Marcela V. Maus, M.D.,Ph.D.","startDate":"2024-09-18","conditions":"Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma","enrollment":28},{"nctId":"NCT01526096","phase":"PHASE1","title":"Stem Cell Transplantation for Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2011-07-12","conditions":"Myeloma","enrollment":30},{"nctId":"NCT02346747","phase":"PHASE2","title":"A Trial of Vigil for Participants With Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gradalis, Inc.","startDate":"2015-02","conditions":"Ovarian Cancer, Ovarian Neoplasms","enrollment":92},{"nctId":"NCT03016871","phase":"PHASE2","title":"Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2017-04-24","conditions":"Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":78},{"nctId":"NCT03630211","phase":"PHASE2","title":"Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2018-07-31","conditions":"Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease","enrollment":8},{"nctId":"NCT05371093","phase":"PHASE3","title":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2022-09-22","conditions":"Relapsed/Refractory Follicular Lymphoma","enrollment":231},{"nctId":"NCT07199296","phase":"PHASE2","title":"Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-07-01","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":45},{"nctId":"NCT06905509","phase":"PHASE2","title":"Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Joseph Tuscano","startDate":"2025-07-31","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements","enrollment":25},{"nctId":"NCT06027983","phase":"PHASE1, PHASE2","title":"Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2026-11-01","conditions":"HER2+ Advanced Breast Cancer, Other Solid Tumors","enrollment":36},{"nctId":"NCT03294954","phase":"PHASE1","title":"GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2018-01-18","conditions":"Neuroblastoma","enrollment":70},{"nctId":"NCT05629546","phase":"PHASE1","title":"Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-11-06","conditions":"Advanced Melanoma, Metastatic Melanoma","enrollment":33},{"nctId":"NCT04007029","phase":"PHASE1","title":"Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-10-04","conditions":"CD19 Positive, CD20 Positive, Recurrent Chronic Lymphocytic Leukemia","enrollment":24},{"nctId":"NCT05039073","phase":"PHASE2","title":"Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors","status":"RECRUITING","sponsor":"Emory University","startDate":"2022-05-02","conditions":"Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma","enrollment":46},{"nctId":"NCT06812858","phase":"PHASE2","title":"PD-1 Inhibitors Maintenance for cHL Post-autoHCT","status":"RECRUITING","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2024-09-02","conditions":"Hodgkin Lymphoma","enrollment":83},{"nctId":"NCT03496779","phase":"PHASE2","title":"Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2018-04-10","conditions":"Refractory Peripheral T-Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma","enrollment":71},{"nctId":"NCT02775292","phase":"PHASE1","title":"Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2017-01-03","conditions":"Adult Solid Neoplasm, Childhood Solid Neoplasm, Metastatic Neoplasm","enrollment":1},{"nctId":"NCT02681302","phase":"PHASE1, PHASE2","title":"Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2016-06-07","conditions":"Multiple Myeloma, Lymphoma","enrollment":46},{"nctId":"NCT04368806","phase":"PHASE2, PHASE3","title":"A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis","status":"RECRUITING","sponsor":"Nature Cell Co. Ltd.","startDate":"2021-05-26","conditions":"Osteoarthritis, Knee","enrollment":140},{"nctId":"NCT02763319","phase":"PHASE2, PHASE3","title":"A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-11-28","conditions":"Diffuse Large B-cell Lymphoma","enrollment":453},{"nctId":"NCT04003649","phase":"PHASE1","title":"IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2019-12-02","conditions":"Recurrent Glioblastoma, Refractory Glioblastoma","enrollment":60},{"nctId":"NCT07053436","phase":"PHASE2","title":"Horizon Two Adaptive Platform Study in High Risk Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Multiple Myeloma Research Consortium","startDate":"2025-10-01","conditions":"High Risk Newly Diagnosed Multiple Myeloma","enrollment":300},{"nctId":"NCT02722668","phase":"PHASE2","title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-05-15","conditions":"Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma","enrollment":15},{"nctId":"NCT06195618","phase":"PHASE1","title":"Personalized Vaccine for TNBC Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Universidad Nacional de Colombia","startDate":"2025-08-01","conditions":"Breast Cancer Female","enrollment":8},{"nctId":"NCT03477500","phase":"PHASE3","title":"Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2018-03-21","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT03645928","phase":"PHASE2","title":"Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2019-05-07","conditions":"Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer","enrollment":245},{"nctId":"NCT07001540","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-05-08","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":130},{"nctId":"NCT07014059","phase":"PHASE2","title":"Autologous Serum Obtained by a Closed-Circuit Collection Device","status":"NOT_YET_RECRUITING","sponsor":"GIANCARLO FATOBENE","startDate":"2025-06-20","conditions":"GVHD, Meibomian Gland Dysfunction (Disorder), Stevens-Johnson Syndrome","enrollment":16},{"nctId":"NCT05265975","phase":"PHASE1, PHASE2","title":"A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL","status":"TERMINATED","sponsor":"Antengene Corporation","startDate":"2022-04-07","conditions":"Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma","enrollment":54},{"nctId":"NCT02953509","phase":"PHASE1, PHASE2","title":"Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2016-11-21","conditions":"Non Hodgkin Lymphoma","enrollment":178},{"nctId":"NCT05775211","phase":"NA","title":"Effects of Intrauterine Administration of Autologous PBMC Modulated With IFNt on Endometrial Cell Populations","status":"RECRUITING","sponsor":"Nadezhda Women's Health Hospital","startDate":"2023-03-13","conditions":"Infertility","enrollment":300},{"nctId":"NCT05775198","phase":"NA","title":"Effect of Intrauterine Administration of Autologous PBMC Modulated With IFNt on IVF Outcome","status":"RECRUITING","sponsor":"Nadezhda Women's Health Hospital","startDate":"2023-03-01","conditions":"Infertility, Female, IVF","enrollment":300},{"nctId":"NCT03057795","phase":"PHASE2","title":"Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2017-04-03","conditions":"Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":62},{"nctId":"NCT01318317","phase":"PHASE1, PHASE2","title":"Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2011-09-19","conditions":"Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma","enrollment":8},{"nctId":"NCT04737889","phase":"PHASE2","title":"Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2021-01-13","conditions":"Primary Central Nervous System Lymphoma","enrollment":30},{"nctId":"NCT06931613","phase":"PHASE2","title":"Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment","status":"ENROLLING_BY_INVITATION","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2022-06-01","conditions":"Relapsed or Refractory Hodgkin Lymphoma, Children, Nivolumab","enrollment":20},{"nctId":"NCT06931041","phase":"PHASE3","title":"Comparing Efficacy of Autologous Serum Eye Drops With and Without Insulin in Autoimmune Dry Eye: A Randomized Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Instituto de Oftalmología Fundación Conde de Valenciana","startDate":"2024-02-01","conditions":"Dry Eye, Sjogren Syndrome","enrollment":25},{"nctId":"NCT03187210","phase":"PHASE1, PHASE2","title":"Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas","status":"SUSPENDED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2018-09-01","conditions":"Lymphoma","enrollment":20},{"nctId":"NCT03440567","phase":"PHASE1","title":"Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2018-04-02","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":16},{"nctId":"NCT01476839","phase":"PHASE1","title":"Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2012-11-09","conditions":"Recurrent Adult Hodgkin Lymphoma","enrollment":25},{"nctId":"NCT04239040","phase":"PHASE1","title":"GVAX Plus Checkpoint Blockade in Neuroblastoma","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-01-29","conditions":"Neuroblastoma, Pediatric Solid Tumor","enrollment":19},{"nctId":"NCT05123014","phase":"NA","title":"Lenticule Implantation and Autologous Serum New Approach in Treatment of Adenoviral Keratitis Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eye Hospital Pristina Kosovo","startDate":"2018-02-01","conditions":"Adenoviral Keratoconjunctivitis","enrollment":45},{"nctId":"NCT03475134","phase":"PHASE1","title":"TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2018-02-21","conditions":"Metastatic Melanoma","enrollment":18},{"nctId":"NCT06816784","phase":"PHASE2","title":"Treatment Options for Chronic Urticaria","status":"NOT_YET_RECRUITING","sponsor":"Sheikh Zayed Medical College","startDate":"2025-02","conditions":"Chronic Urticaria","enrollment":72},{"nctId":"NCT06803758","phase":"NA","title":"Teicoplanin Allergy Testing Using Autologous Serum (TATAS)","status":"RECRUITING","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2025-01-08","conditions":"Drug Allergy","enrollment":20},{"nctId":"NCT04634435","phase":"PHASE1","title":"Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Biohaven Pharmaceuticals, Inc.","startDate":"2021-10-21","conditions":"Multiple Myeloma","enrollment":7},{"nctId":"NCT03707808","phase":"PHASE1, PHASE2","title":"Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab","status":"RECRUITING","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2018-01-29","conditions":"Solid Tumor, Metastases to Soft Tissue","enrollment":18},{"nctId":"NCT01413100","phase":"PHASE2","title":"Scleroderma Treatment With Autologous Transplant (STAT) Study","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2011-09-15","conditions":"Systemic Scleroderma","enrollment":21},{"nctId":"NCT06734663","phase":"NA","title":"Clinical Outcomes of Sutured Versus Sutureless Conjunctival Autograft in Primary Pterygium Excision","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-12-15","conditions":"Pterygium of Conjunctiva and Cornea, Pterygium of Both Eyes, Pterygium","enrollment":70},{"nctId":"NCT03921515","phase":"EARLY_PHASE1","title":"Skin Immunity Sample Collection Involving Blisters and Biopsies","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-12-09","conditions":"Hyper-Immunoglobulin E. Syndrome (HEIS), Chronic Granulomatous Disease (CGD)","enrollment":""},{"nctId":"NCT05221645","phase":"PHASE2","title":"Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southampton","startDate":"2022-06-27","conditions":"Diffuse Large B Cell Lymphoma","enrollment":65},{"nctId":"NCT01919619","phase":"PHASE2","title":"Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-11-04","conditions":"B-Cell Non-Hodgkin Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Leukemia","enrollment":41},{"nctId":"NCT04168502","phase":"PHASE3","title":"Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML","status":"RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2020-09-24","conditions":"Acute Myeloid Leukemia","enrollment":414},{"nctId":"NCT03296137","phase":"PHASE1, PHASE2","title":"Adoptive Cell Therapy Across Cancer Diagnoses","status":"COMPLETED","sponsor":"Inge Marie Svane","startDate":"2017-10-13","conditions":"Cancer","enrollment":25},{"nctId":"NCT05889585","phase":"NA","title":"Morbidity, Long-term Side Effects and Quality of Life in Germ-cell Tumor Long Survivors Treated with High-dose Chemotherapy and Autologous Stem Cell Transplant","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2023-05-31","conditions":"Germ Cell Tumor","enrollment":180},{"nctId":"NCT04624958","phase":"PHASE2","title":"Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-12-01","conditions":"Mantle Cell Lymphoma, Newly-diagnosed Mantle Cell Lymphoma","enrollment":42},{"nctId":"NCT02027935","phase":"PHASE2","title":"CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-01-22","conditions":"Metastatic Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7","enrollment":16}],"_emaApprovals":[],"_faersSignals":[{"count":9,"reaction":"EYE PAIN"},{"count":3,"reaction":"DRUG INEFFECTIVE"},{"count":3,"reaction":"LACRIMATION INCREASED"},{"count":3,"reaction":"OCULAR DISCOMFORT"},{"count":3,"reaction":"PERIORBITAL PAIN"},{"count":3,"reaction":"PHOTOPHOBIA"},{"count":2,"reaction":"DIARRHOEA"},{"count":2,"reaction":"EYE IRRITATION"},{"count":2,"reaction":"EYE SWELLING"},{"count":2,"reaction":"EYELID PTOSIS"}],"_approvalHistory":[],"publicationCount":2257,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AS","GSA"],"phase":"marketed","status":"active","brandName":"Autologous serum","genericName":"Autologous serum","companyName":"Anita Syla Lokaj","companyId":"anita-syla-lokaj","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Autologous serum is a patient's own blood serum used topically to provide growth factors and immunomodulatory components that promote tissue healing and reduce inflammation. Used for Severe dry eye syndrome/keratoconjunctivitis sicca, Ocular surface disease refractory to conventional therapy, Stevens-Johnson syndrome ocular complications.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}